BREUIL ROBERT S 4
4 · CalciMedica, Inc. · Filed Mar 27, 2023
Insider Transaction Report
Form 4
BREUIL ROBERT S
Chief Financial Officer
Transactions
- Tax Payment
Common Stock
2023-03-23$5.50/sh−12,677$69,724→ 35,326 total - Disposition to Issuer
Common Stock
2023-03-23+36,657→ 48,003 total - Disposition to Issuer
Restricted Stock Unit
2023-03-23−36,657→ 0 total→ Common Stock (36,657 underlying)
Footnotes (1)
- [F1]Reflects a 14-to-1 reverse stock split effective March 17, 2023. Under the terms of the Agreement and Plan of Merger and Reorganization, dated as of November 21, 2022, as amended (the "Merger Agreement"), by and among CalciMedica, Inc. ("Private CalciMedica"), the Issuer and Camaro Merger Sub, Inc., a wholly-owned subsidiary of the Issuer ("Merger Sub"), on March 20, 2023, Merger Sub merged with and into Private CalciMedica (the "Merger"), with Private CalciMedica surviving the Merger as a wholly-owned subsidiary of the Issuer. Upon the closing of the Merger, each share of CalciMedica common capital stock was converted into the right to receive 0.0288 of a share of the Issuer's common stock. Subsequent to the Merger, the name of the Issuer was changed from Graybug Vision, Inc. to CalciMedica, Inc. In connection with the Merger, the vesting of Robert S. Breuil's options and restricted stock units ("RSUs") were fully accelerated and the RSUs were settled on March 23, 2023.